Use of milrinone to support therapy-induced heart failure through hematopoietic stem cell transplantation in a pediatric patient with high-risk FLT3+acute myeloid leukemi

Pediatric Blood & CancerEarly View e30542 LETTER TO THE EDITOR Use of milrinone to support therapy-induced heart failure through hematopoietic stem cell transplantation in a pediatric patient with high-risk FLT3+ acute myeloid leukemi Brianna Gerhartz, Brianna Gerhartz Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorSudarshawn Damodharan, Sudarshawn Damodharan Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorDiane M. Puccetti, Diane M. Puccetti Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorJuan P. Boriosi, Juan P. Boriosi Division of Pediatric Critical Care Medicine, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorJohn S. Hokanson, John S. Hokanson Division of Pediatric Cardiology, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorChristian M. Capitini, Corresponding Author Christian M. Capitini [email protected] Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA Correspondence Christian Capitini, Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, 1111 Highland Avenue, WIMR 4137, Madison, WI 53705, USA. Email: [email protected]Search for more papers by this author Brianna Gerhartz, Brianna Gerhartz Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorSudarshawn Damodharan, Sudarshawn Damodharan Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorDiane M. Puccetti, Diane M. Puccetti Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorJuan P. Boriosi, Juan P. Boriosi Division of Pediatric Critical Care Medicine, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorJohn S. Hokanson, John S. Hokanson Division of Pediatric Cardiology, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USASearch for more papers by this authorChristian M. Capitini, Corresponding Author Christian M. Capitini [email protected] Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, USA Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA Correspondence Christian Capitini, Department of Pediatrics, University of Wisconsin School of Medicine & Public Health, 1111 Highland Avenue, WIMR 4137, Madison, WI 53705, USA. Email: [email protected]Search for more papers by this author First published: 23 July 2023 https://doi.org/10.1002/pbc.30542Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Pollard JA, Alonzo TA, Gerbing R, et al. Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3/ITD+ acute myeloid leukemia: a report from the Children's Oncology Group Protocol AAML1031. J Clin Oncol. 2022; 40(18): 2023- 2035. 2Shukla N, Kobos R, Renaud T, Steinherz LJ, Steinherz PG. Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia. Pediatr Blood Cancer. 2014; 61(3): 431- 435. 3Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020; 105(6): 1507- 1516. 4Getz KD, Sung L, Ky B, et al. Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: a report from the Children's Oncology Group. J Clin Oncol. 2019; 37(1): 12- 21. 5Chen MH, Kerkela R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008; 118(1): 84- 95. 6Ma W, Liu M, Liang F, et al. Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis. Basic Clin Pharmacol Toxicol. 2020; 126(2): 166- 180. 7Peres E, Levine JE, Khaled YA, et al. Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010; 45(1): 149- 152. 8Sengsayadeth S, Savani BN, Blaise D, Malard F, Nagler A, Mohty M. Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission—a review from the Acute Leukemia Working Party of the EBMT. Haematologica. 2015; 100(7): 859- 869. 9Roloff GW, Odenike O, Bajel A, Wei AH, Foley N, Uy GL. Contemporary approach to acute myeloid leukemia therapy in 2022. Am Soc Clin Oncol Educ Book. 2022; 42: 1- 16. 10Ayres JK, Maani CV. Milrinone. StatPearls. Treasure Island, FL. 2023. 11Bishara T, Seto WT, Trope A, Parshuram CS. Use of milrinone in critically ill children. Can J Hosp Pharm. 2010; 63(6): 420- 428. Early ViewOnline Version of Record before inclusion in an issuee30542 ReferencesRelatedInformation